Novo Nordisk plans to launch its oral weight-loss drug, Wegovy, in international markets later this year pending regulatory approvals. The company’s executive vice president for international operations identifies significant opportunities beyond the U.S. and plans an aggressive expansion.
The move follows a successful U.S. introduction where total prescriptions have exceeded two million. This global push serves as a primary strategy for new growth amid intensifying competition in the obesity drug sector.
Novo Nordisk faces increasing pricing pressures in the U.S. and looming generic competition in markets like India and Canada. Management expects strong demand for Wegovy in new territories despite these market challenges.